anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Determine screening rates and examine socio-demographic characteristics of metabolic dysfunction-associated steatotic liver disease (MAFLD) screening in a large population of obese children.
METHODS: We used Explorys (IBM) which contains aggregated population-level electronic health record data from approximately 360 hospitals and 317,000 providers across the United States to determine MAFLD screening rates. In children 10 to 14 years, obesity was determined based on body mass index ≥ 95%, or encounter with an international classification of disease obesity code. We determined screening rates by calculating the percentage of children with obesity who had an alanine aminotransferase tested, further analyzed by gender, race, and insurance.
RESULTS: Of 3,558,420 children, 513,170 (14.4%) were obese. Of obese children, only 9.3% were screened for MAFLD. Females were more likely screened than males (odds ratio (OR) 1.09 (95% confidence intervals (CI): 1.07-1.12)); White children were more likely screened than non-White children (OR 1.21 (95% CI: 1.18-1.23)), and children with Medicaid more likely screened than children with non-Medicaid insurance (OR 1.34 (95% CI: 1.32-1.37)).
CONCLUSIONS: The percentage of obese children receiving screening for MAFLD was low. Female gender, White race, and Medicaid insurance were associated with increased screening rates. These findings highlight the need to increase adherence to MAFLD screening. Reporting screening as a health quality measure may reduce implementation gaps in MAFLD screening.
The electrocardiograms for 338 patients who received mirtazapine tablets and 261 patients who received placebo in 6-week, placebo-controlled trials were analyzed. Prolongation in QTc ≥ 500 msec was not observed among mirtazapine-treated patients; mean change in QTc was +1.6 msec for mirtazapine and –3.1 msec for placebo. Mirtazapine was associated with a mean increase in heart rate of 3.4 bpm, compared to 0.8 bpm for placebo. The clinical significance of these changes is unknown. 

The effect of mirtazapine on QTc interval was assessed in a clinical randomized trial with placebo and positive (moxifloxacin) controls involving 54 healthy volunteers using exposure response analysis. This trial showed a positive relationship between mirtazapine concentrations and prolongation of the QTc interval. However, the degree of QT prolongation observed with both 45 mg (therapeutic) and 75 mg (supratherapeutic) doses of mirtazapine was not at a level generally considered to be clinically meaningful.
The plan is to enroll 20 patients, who will be randomly assigned in a 1:1 ratio to the experimental group and the control group according to the protocol criteria. The control group will undergo routine bronchoscopy examination, lavage, and mucosal biopsy.
A system is provided for enabling a user to overcome submissiveness. The system is configured to enable the user to engage in a first and a second activity in a virtual environment, directed to rewire a first and a second defective wiring, respectively. The first defective wiring results in an individual inclining towards the fear of retaliation and/or losing good impression. The second defective wiring results in inability to weigh between the benefits of disagreeing and the fear of retaliation and/or losing good impression. Symptom of the first and the second defective wirings is submissiveness. Engagement in the second activity is enabled after the user has at least participated in the first activity. Automated instructions are provided to the user to engage in activities performed in a real world environment directed to rewire the first and the second defective wiring.
The participant will visit the clinical trial institution at 4, 8, 12, and 16 weeks after the application visit (Visit 2, Baseline) of the medical device for clinical trials. They will participate in the efficacy evaluation of the clinical trial medical device for a total of 16 weeks.
The invention discloses a foot-bath composition for treating dermatophytosis and belongs to the technical field of traditional Chinese medicine health products. The foot-bath composition is prepared from 5-15g of saffron, 5-15g of radix sophorae flavescentis, 5-15g of rhizoma smilacis glabrae, 5-15g of fructus forsythia, 10-20g of rhizoma atractylodis, 10-20g of Chinese gall, 10-20g of ash bark, 10-20g of clove, 10-20g of coptis root, 15-25g of phellodendron and 25-35g of plantain herb. Through combination of the above traditional Chinese medicines, medical synergism is produced. Rhizoma smilacis glabrae, phellodendron and plantain herb have effects of clearing heat and draining dampness. Saffron and clove have effects of warming yang and dispelling cold. Fructus forsythiae and Chinese gall have effects of removing toxins and killing parasite. Radix sophorae flavescentis, rhizoma atractylodis and coptis root have effects of eliminating dampness and relieving itching. Through compatibility of the above traditional Chinese medicines, the foot-bath composition has effects of clearing heat and draining dampness, warming yang and dispelling cold, removing toxins and killing parasite, and eliminating dampness and relieving itching. A clinical test on 60 patients suffering from dermatophytosis proves that the foot-bath composition has the total effective rate of 98.2%, difficult recurrence and no toxic or side effect.
PURPOSE: A pharmaceutical composition containing Juncus effusus extract for preventing or treating inflammatory or immune disease is provided to suppress activation of NF-kappaB(nuclear factor kappa B) and expression of TNF-alpha(tumor necrossi factor-alpha) and NO(nitrogen oxide). CONSTITUTION: A composition for preventing or treating inflammatory or immune diseases contains Juncus effuses extract as an active ingredient. The composition for treating or preventing inflammatory or immune diseases contain canthoside derivative of chemical formula 1 or its pharmaceutically acceptable salt as an active ingredient. In the chemical formula 1, R1 to R5 independently H, OMe, COOMe or OH. The canthoside derivative is isolated from Juncus effuses using solvent. The solvent is water, methanol, ethanol, butanol, chloroform, hexane, ethylaceate, dichloromethane, or their mixture.
Long-term weight outcomes reflect the success of obesity treatment. Weight regain during treatment for obesity is a biologically maladaptive response that can be considered a central feature of the disease. This phenomenon has been well documented in patients treated with lifestyle changes and bariatric surgery. In patients treated with liraglutide 3.0 mg this has been documented in randomized control trials, but real-world analysis is lacking. The aim of this retrospective observational study was to explore the long-term weight outcomes in patients treated with liraglutide 3.0 mg in a real-world clinical practice. The association between body composition changes and weight outcomes was also explored. The study included 25 patients treated with multi-modal care that included liraglutide 3.0 mg over a period of 78 weeks. Body composition was examined via dual x-ray absorptiometry at 16 and 32 weeks, with body weight captured up until 78 weeks for all patients. Weight loss (R2  = 0.39, p < .001), fat mass loss (R2  = 0.32, p = .003) and fat-free mass loss (R2  = 0.19, p = .03) were all associated with weight change from artificial nadir, which was, on average, 3.8 kg. For body composition, after adjustment, only fat mass loss was associated weight regain (R2  = 0.32, p = .01). In conclusion, in patients with clinical obesity treated with liraglutide 3.0 mg in a real-world clinical setting, fat mass loss was associated with weight regain. Whilst weight regain occurred on average, the magnitude was less than that observed in patients treated with lifestyle alone and weight loss remained clinically significant for most patients.
Upon enrollment in the study, patients will undergo radiation simulation. Protocol therapy will start upon completion of RT planning (1-2 weeks). Chemoradiation will be initiated 1-2 weeks later depending on RT planning and consist of whole liver irradiation (WLI).
PURPOSE:To obtain a herb drug having anti-trichophyton activity and free from side effect, by extracting a fermented and cultured Artemisia vulgaris and/or Macleya cardata, drying the extract at low temperature to remove water therefrom and, at the same time, absorbing and drying the cultured liquid. CONSTITUTION:Artemisia vulgaris and/or Macleya cardata or their mixture with one or two other herbs is subjected to fermentative cultivation and extraction. The extracted liquid is dried at a low temperature and again allowed to absorb in said substance to obtain the objective Chinese herb drug. The drug has high impregnation activity into cuticle layer which is a pathogenic layer of trichophyton, exterminates the trichophyton, promotes metabolism of cured cuticle layer and facilitates the recovery of the cuticle layer. The fermentative cultivation period is 20-30 days. The obtained herb drug is immersed in 200cc of an alkaline SHOCHU (low-class distilled spirit) at an amount of 20% and left standing for 24hr. Itchiness of the diseased part can be eliminated in 2-3 days by applying the liquid to the part once or twice a day.
BACKGROUND: Acute pain management is critical in sports-related musculoskeletal injuries to facilitate recovery and minimize long-term impact. While current practices vary, incorporating both pharmacological and non-pharmacological approaches, the quality and breadth of existing evidence have not been thoroughly assessed. This scoping review aims to explore the clinical role of different pain management strategies and provide a comprehensive overview of the field.
METHODS: The review will follow the Joanna Briggs Institute (JBI) methodology for scoping reviews and adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Scoping Reviews (PRISMA-ScR) guidelines. Searches will be conducted in major peer-reviewed databases and relevant gray literature. Studies involving athletes of any level undergoing treatment for acute musculoskeletal injuries will be considered. Data extraction will include study and participant characteristics, intervention details, reported outcomes, efficacy comparisons, and economic analyses.
RESULTS: This review will provide a descriptive synthesis of the data, utilizing statistical analysis, figures, and tables where relevant to introduce the different treatment modalities. In line with PRISMA-P and PRISMA-ScR guidelines, this scoping review incorporates studies of diverse designs. The data synthesis involves descriptive statistics and narrative presentations, aimed at exploring the relationship between study results and research objectives.
CONCLUSION: This scoping review will evaluate various pain management interventions for acute musculoskeletal injuries in sports, mapping the current evidence and identifying gaps in research. The findings will help inform clinical practices and guide future research efforts to optimize pain management strategies in sports medicine.
The objective of this study is to evaluate the accuracy of trapeziometacarpal injections using palpation alone. If it can be shown that the accuracy of trapeziometacarpal injections using palpation alone is similar to the reported accuracy of ultrasound and fluoroscopy, then fluoroscopy and ultrasound guided techniques may not be needed. Due to the expenses associated with medications and testing, it is important to not accrue unnecessary costs if there is no perceived benefit. The investigators plan to enroll 50 patients presenting with trapeziometacarpal joint arthritis who agree to participate. These participants will undergo an injection technique consisting of palpating the base of the thumb and placing the needle into the trapeziometacarpal joint without the guidance of ultrasound or fluoroscopy. Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 fluoroscopy views of the thumb. The images will not be evaluated for injection accuracy prior to the patient leaving the clinic, so as to not introduce any bias by the treating physician. These images will be blindly reviewed by three investigators at a later date, and determined by consensus if there is contrast material in the joint. The accuracy rate can then be compared to data regarding accuracy of fluoroscopic and ultrasound guided injections of the trapeziometacarpal joint. If there is a similar accuracy rate between modalities, it can be concluded that ultrasound may not be worth the added cost to the patient and fluoroscopy may not be worth the added cost or radiation to the participant. Additionally, participants will be contacted at 6 weeks post injection to evaluate post-injection arthritis symptoms.
This narrative review explores the pathophysiology of obesity, cellular senescence, and exosome release. When exposed to excessive nutrients, adipocytes develop mitochondrial dysfunction and generate reactive oxygen species with DNA damage. This triggers adipocyte hypertrophy and hypoxia, inhibition of adiponectin secretion and adipogenesis, increased endoplasmic reticulum stress and maladaptive unfolded protein response, metaflammation, and polarization of macrophages. Such feed-forward cycles are not resolved by antioxidant systems, heat shock response pathways, or DNA repair mechanisms, resulting in transmissible cellular senescence via autocrine, paracrine, and endocrine signaling. Senescence can thus affect preadipocytes, mature adipocytes, tissue macrophages and lymphocytes, hepatocytes, vascular endothelium, pancreatic β cells, myocytes, hypothalamic nuclei, and renal podocytes. The senescence-associated secretory phenotype is closely related to visceral adipose tissue expansion and metaflammation; inhibition of SIRT-1, adiponectin, and autophagy; and increased release of exosomes, exosomal micro-RNAs, pro-inflammatory adipokines, and saturated free fatty acids. The resulting hypernefemia, insulin resistance, and diminished fatty acid β-oxidation lead to lipotoxicity and progressive obesity, metabolic syndrome, and physical and cognitive functional decline. Weight cycling is related to continuing immunosenescence and exposure to palmitate. Cellular senescence, exosome release, and the transmissible senescence-associated secretory phenotype contribute to obesity and metabolic syndrome. Targeted therapies have interrelated and synergistic effects on cellular senescence, obesity, and premature aging.
Cells respond divergently to drugs due to the heterogeneity among cell populations. Thus, it is crucial to identify drug-responsive cell populations in order to accurately elucidate the mechanism of drug action, which is still a great challenge. Here, we address this problem with scRank, which employs a target-perturbed gene regulatory network to rank drug-responsive cell populations via in silico drug perturbations using untreated single-cell transcriptomic data. We benchmark scRank on simulated and real datasets, which shows the superior performance of scRank over existing methods. When applied to medulloblastoma and major depressive disorder datasets, scRank identifies drug-responsive cell types that are consistent with the literature. Moreover, scRank accurately uncovers the macrophage subpopulation responsive to tanshinone IIA and its potential targets in myocardial infarction, with experimental validation. In conclusion, scRank enables the inference of drug-responsive cell types using untreated single-cell data, thus providing insights into the cellular-level impacts of therapeutic interventions.
The objective of this study is to evaluate paired-pulse inhibition of the three responses of the electrically elicited blink reflex (BR) and the eye blink rate (EBR)in patients with craniofacial dystonia and their first degree relatives in order to determine whether abnormalities of inhibition can represent a marker of genetic predisposition for the development of dystonia. It is unclear why some relatives of patients with craniofacial dystonia do not develop dystonic symptoms. One possible explanation is that the development of dystonia is a two-stage process: first, loss of inhibition, which may be genetically determined, and second, exposure to an environmental trigger such as excessive repetitive movements. There is good evidence that focal dystonia is a genetically determined disorder, but the responsible gene remains undetermined. Patients, their first degree relatives and normal volunteers will undergo BR testing using validated electrophysiological tests of recovery cycle. The main outcome measure of the study is impaired inhibition in up to 50% of first degree relatives of patients with focal dystonia which would serve as biologic marker for the carrier state. A second outcome measure is the EBR. In those individuals with this genetic marker of impaired inhibition, future linkage analysis studies could be performed to identify the causative gene.
MANEC, a subtype of MiNEN, is a rare disease, even rarer when found in the remnant stomach. We report a residual gastric MANEC case found 44 years after subtotal gastrectomy. The patient was an 80-year-old female who underwent subtotal gastrectomy at 36 years old and was referred to our hospital for anorexia and weight loss. An elevated lesion(tub2> tub1)was found on the oral side of the anastomosis. Endoscopic submucosal dissection(ESD)was performed, which revealed MANEC with SM or deeper, ly1, HM?, and VM1, prompting referral for additional surgical resection. Completion remnant gastrectomy was performed. Pathological results showed 2 metastases in the left cardia lymph node and no residual cancer in the remnant stomach. The patient had a recurrence 9 months later and died 11 months after surgery. This case corresponds to not only MiNEN but also MANEC, and only 2 cases of remnant stomach MANEC(MiNEN)could be retrieved in PubMed. MANEC(MiNEN)is considered to have a poor prognosis. In this case, left cardia lymph node metastasis prompted a splenectomy, aiming to improve curability. However, the death of the patient 11 months post-surgery suggested that the disease displayed high malignant potential. Considering the high invasiveness of MANEC, lymphadenectomy and multidisciplinary treatment strategies should be considered. However, careful examination is necessary to see if they contribute to the prognosis.
A respiratory or surgical humidifier having communication capabilities for communicating with other medical devices. The humidifier can obtain updates from the other medical devices and transmit and receive other data using the communication capabilities. The humidifier's operational state can be logged and its health can be assessed by another device. The humidifier's operation can be controlled based on data communicated from other medical devices. Also disclosed are other medical devices for communicating with the humidifier. Also disclosed are methods by which devices of a humidification and ventilation system can authenticate each other.
Opaque, sterile, non-pyrogenic, semi-solid, cohesive implant whose component is synthetic CaHA suspended in a gel carrier of glycerin, sodium carboxymethylcellulose, 0.3% lidocaine hydrochloride, and sterile water. Treatment injection follows product instruction.
Intervention: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
<P>PROBLEM TO BE SOLVED: To provide a dental restorative material that has sufficient strengths as a fiber-reinforced resin material for dental restoration and excellent workability in restoration, and an artificial tooth using the material.  <P>SOLUTION: The dental restorative material is the fiber-reinforced resin material that is obtained by impregnating glass fibers with a resin to be cured by light and/or heat in which the glass fibers have 18-50μm filament diameter. The volume content of the glass fibers in the dental restorative material is preferably 50-65%. The dental restorative material is preferably used in a retainer and coupling device of bridge, retainer construction, crown, maintainer and connector of a partial plate denture and a material for tooth fixation. For example, a reinforcing material formed by the dental restorative material 20 provides an artificial tooth 10 to be embedded in or laid in a resin denture base 11.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
BACKGROUND: Ultraviolet (UV)-induced fluorescence technology is widely used in dermatology to identify microbial infections. Our clinical observations under an ultraviolet-induced fluorescent dermatoscope (UVFD) showed red fluorescence on the scalps of androgenetic alopecia (AGA) patients. In this study, based on the hypothesis that microbes are induced to emit red fluorescence under UV light, we aimed to explore the microbial disparities between the AGA fluorescent area (AF group) and AGA non-fluorescent area (ANF group).
METHODS: Scalp swab samples were collected from 36 AGA patients, including both fluorescent and non-fluorescent areas. The bacterial communities on the scalp were analyzed by 16S rRNA gene sequencing and bioinformatics analysis, as well as through microbial culture methods.
RESULTS: Significant variations were observed in microbial evenness, abundance composition, and functional predictions between fluorescent and non-fluorescent areas. Sequencing results highlighted significant differences in Cutibacterium abundance between these areas (34.06% and 21.36%, respectively; p < 0.05). Furthermore, cultured red fluorescent colonies primarily consisted of Cutibacterium spp., Cutibacterium acnes, Staphylococcus epidermidis, and Micrococcus spp.
CONCLUSIONS: This is the first study to investigate scalp red fluorescence, highlighting microbial composition variability across different scalp regions. These findings may provide novel insights into the microbiological mechanisms of AGA.
PCT No. PCT/DE95/01164 Sec. 371 Date May 20, 1997 Sec. 102(e) Date May 20, 1997 PCT Filed Aug. 18, 1995 PCT Pub. No. WO96/05866 PCT Pub. Date Feb. 29, 1996The invention concerns the preparation and use of a live tumour-cell vaccine which contains three additional genes prepared by genetic-engineering techniques: a) a gene coding for a cell-surface protein with immunostimulatory activity, b) a cytokin gene and c) the thymidine kinase gene. The fields of application of the invention are medicine and genetic engineering. The live vaccine proposed owes its effect to the fact that a synergistic anti-tumour response is induced by the multiple transfer of genes which code for immunostimulatory activity. This leads to reliable repulsion of the vaccine cells and enables cells capable of multiplying to be injected as a vaccine. As an additional safety marker, the vaccine cells are given the thymidine kinase gene which enables the vaccine cells to be selectively killed in vivo. The combinatory expression of genes with immunostimulatory activity improves the vaccine effect in comparison with prior art tumour-cell vaccines, and a live tumour-cell vaccine is more effective than a vaccine consisting of cells which are incapable of multiplying. The vaccine is intended for use in the genetic therapy of cancer patients.